In this article
Peptides for muscle growth are heavily promoted, yet none is FDA-approved for building muscle in healthy adults. Growth hormone secretagogues such as CJC-1295 and ipamorelin can lift growth hormone and IGF-1 levels in short studies, but no controlled trial has shown that this translates into bigger or stronger muscles.
- No randomized human trial has shown a peptide increasing muscle size or strength in healthy adults.
- Secretagogue studies tracked hormone levels rather than muscle; IGF-1 LR3 and MGF have essentially no clinical trials.
- Tesamorelin is licensed only for abdominal fat in HIV-associated lipodystrophy.
- Lifting weights and eating enough protein are still the approaches backed by trials.
- Every compound discussed here is prohibited in competitive sport.
Do peptides help build muscle?
Not in any way that has been demonstrated. Muscle accumulates when the body builds protein faster than it breaks it down over a sustained period, and the strongest known stimulus is mechanical tension from resistance training, which works through the mTOR pathway inside muscle fibers.
Peptides are proposed to work on supporting systems, namely the growth hormone (GH) and IGF-1 axis, satellite cells or mitochondria. The central gap is that a higher hormone level does not equal more muscle, and the trial connecting the two in healthy people has not been done.
How the GH and IGF-1 axis works
- The pituitary gland releases GH in bursts.
- GH prompts the liver to produce IGF-1.
- IGF-1 attaches to muscle receptors and feeds into the same mTOR signaling that training uses.
Secretagogues act at the first step and IGF-1 analogs at the third, which is why the evidence differs so much from compound to compound.
What peptides build muscle? The compounds people ask about
CJC-1295 and ipamorelin
Both prompt your own pituitary to release more GH, using different receptors: CJC-1295 imitates growth hormone-releasing hormone, whereas ipamorelin stimulates the ghrelin receptor. The main human evidence for CJC-1295 is a pair of placebo-controlled studies in healthy adults, published in 2006, that ran 28 and 49 days. After one injection, average GH rose between two and ten times for at least six days, and IGF-1 climbed by roughly 1.5 to 3 times over nine to eleven days. The studies did not assess muscle size, strength or body composition.
Ipamorelin was first described in 1998 as a selective GH secretagogue, releasing GH in rats and pigs without raising cortisol or ACTH. The sole randomized human trial examined it for bowel paralysis after surgery rather than for muscle, and on its main endpoints it did no better than placebo. Nobody has run a controlled trial of the popular pairing itself. See the CJC-1295 and ipamorelin stack, its research page and the ipamorelin page.
Tesamorelin
Tesamorelin is the only GH-axis peptide with a current FDA label, and the label is narrow: lowering surplus belly fat in adults with HIV-related lipodystrophy. It is not meant for weight loss, and its long-term effects on the heart have not been established. The label notes a slight gain in lean body mass in the two 26-week pivotal studies, against a slight loss with placebo, yet those trials were built to measure visceral fat. The label directs monitoring of IGF-1 and blood sugar. See the tesamorelin page and ipamorelin vs sermorelin vs tesamorelin.
Sermorelin
Sermorelin used to be marketed as Geref, which FDA now lists as discontinued. No sermorelin product currently carries approval for building muscle or changing body composition. See the sermorelin page.
IGF-1 LR3
IGF-1 LR3 is an engineered form of IGF-1 built to latch onto carrier proteins less tightly, so more of it stays free and active. It has no approval anywhere, and a PubMed search for clinical trials finds none. Statements about muscle effects are extrapolated from how natural IGF-1 behaves in cells and animals. The one approved IGF-1 medicine, mecasermin, addresses growth failure in children with severe IGF-1 deficiency. Compare it with GH in IGF-1 LR3 vs HGH, or see the research page.
MGF (mechano growth factor)
MGF is a splice variant of IGF-1 discussed in relation to muscle repair. Evidence is limited and mostly preclinical, and no established human trials show it builds muscle. See the MGF page.
MOTS-c
A 2021 paper in Nature Communications found that MOTS-c improved physical performance in young, middle-aged and older mice. Its human component was observational only: exercise increases the body’s own MOTS-c. That is grounds for further study, not a basis for injecting it to gain muscle. See the MOTS-c guide.
What is the best peptide for muscle growth?
No evidence-based answer exists, since none has been tested for this goal in healthy people. Ordered by strength of human data, tesamorelin and mecasermin are approved but only for narrow, unrelated conditions, CJC-1295 has brief hormone-focused trials, and the remainder are preclinical or untested.
| Compound | Human evidence | Regulatory status |
|---|---|---|
| Tesamorelin | Randomized trials in HIV lipodystrophy; lean mass was secondary | FDA-approved for that use only |
| CJC-1295 | Two short trials with hormone endpoints | Not FDA-approved |
| Ipamorelin | One ileus trial, no benefit over placebo | Not FDA-approved |
| IGF-1 LR3 | No clinical trials | Not FDA-approved |
| MGF | Limited, mostly preclinical | Not FDA-approved |
| MOTS-c | Mouse data plus human observation | Not FDA-approved |
For how regulators treat these compounds, see are peptides legal.
Is there a peptide stack for muscle growth?
Popular online stacks combine a growth hormone-releasing hormone analog with a ghrelin-receptor agonist, typically CJC-1295 with ipamorelin, on the theory that two pathways produce a bigger GH pulse. That is a pharmacological hypothesis, not a demonstrated muscle result, and safety data remain limited. Research-reported ranges are on the peptide dosage chart; any use should be discussed with a qualified clinician.
Do peptides increase testosterone?
The compounds above work on the growth hormone axis rather than on testosterone, and none has been shown to raise it. Peptides acting on the reproductive axis, such as kisspeptin, are studied for triggering luteinizing hormone, but evidence on testosterone outcomes is early. Low testosterone is a medical diagnosis best assessed by a clinician with blood work; the Bloodwork Panel Planner can help you prepare questions.
Peptides and muscle on GLP-1 drugs
Here the human data are strongest. A 2026 meta-analysis pooling 20 randomized trials and 15,782 participants found that lean tissue accounted for 25 to 39 percent of the weight lost on incretin drugs, close to the 26.2 percent seen with dieting alone. Adding resistance training to a lifestyle program cut it to 17.5 percent. In the SURMOUNT-1 body-composition substudy, roughly three quarters of the weight lost was fat and a quarter was lean mass. Lean mass also includes water and organ tissue, so it overstates muscle loss. See peptides for weight loss.
Frequently asked questions
Do peptides really build muscle?
No peptide has been shown in a randomized trial to add muscle or strength in healthy adults. Training and protein intake have the supporting trial evidence.
Are muscle peptides FDA-approved or legal?
Tesamorelin and mecasermin are approved for specific conditions. CJC-1295, ipamorelin, IGF-1 LR3, MGF and MOTS-c are not approved for any use.
Are peptides banned in sport?
Yes. WADA’s Prohibited List covers GHRH analogs, GH secretagogues, IGF-1 and its analogs, and MOTS-c, at all times.
Do GLP-1 drugs cause muscle loss?
They cause some lean-mass loss alongside fat loss, in a share similar to dieting alone. Resistance training reduced it in trials.
Where can I find compounds by goal?
Try peptides by goal or ask Pulse, and involve a qualified clinician.
References
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006 — pubmed.ncbi.nlm.nih.gov
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998 — pubmed.ncbi.nlm.nih.gov
- Beck DE et al. Randomized proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Int J Colorectal Dis, 2014 — pubmed.ncbi.nlm.nih.gov
- Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 2021 — pubmed.ncbi.nlm.nih.gov
- Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: systematic review and meta-analysis. Diabetes Obes Metab, 2026 — pubmed.ncbi.nlm.nih.gov
- Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab, 2025 — pubmed.ncbi.nlm.nih.gov
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



